Chromadex and Lifeway Foods NAD+ and microbiome innovations inform reconstitution of stock indexes
04 Jul 2024 --- Chromadex, an authority on nicotinamide adenine dinucleotide (NAD+) research, and Lifeway Foods, a microbiome-supporting kefir supplier, have been included in the Russell 2000 Index as part of the annual reconstitution of its stock indexes.
“Joining the Russell 2000 Index reflects our sustained growth and leadership in NAD+ research. Tru Niagen is the gold standard NAD+ supplement, backed by scientific rigor, the highest quality standards and a robust intellectual property portfolio,” says Rob Fried, CEO of ChromaDex and founder of Tru Niagen.
“This achievement underscores our commitment to driving long-term value for our shareholders as we expand our global footprint, innovate with new products and advance the science of healthy aging.”
The annual Russell Indexes reconstitution captures the 4,000 most extensive US stocks as of Friday. Membership in the US all-cap Russell 3000 Index, which lasts for one year, guarantees automatic inclusion in either the large-cap Russell 1000 Index or the small-cap Russell 2000 Index, along with the appropriate growth and value style indexes.
Probiotic products and microbiome portfolio
Lifeway Foods has been included in the Russell 2000 Index, the Russell 3000 Index and the Russell Reconstitution. The Russell Reconstitution rebalances the portfolio’s US Indexes family to maintain an accurate representation of equity markets.
“With our recent earnings report marking an incredible string of 18 consecutive quarters of revenue growth and four consecutive quarters of record net sales, we welcome the elevated visibility within the investment community,” says Julie Smolyansky, president and chief executive officer of Lifeway Foods.
“Being part of the Russell indexes enhances our visibility to the many institutions and funds that consider them a key market reference point. We are excited about the opportunity to increase our exposure and continue creating shareholder value.”
NAD+ supplement performs well
ChromaDex’s Tru Niagen proprietary supplement has strong financial performance and a robust intellectual property portfolio. The team works with independent investigators from universities and research institutions worldwide to learn about the potential of NAD+. The NAD+ coenzyme declines with age, accelerating a decline in vitality.
The company’s patented nicotinamide riboside ingredient, Niagen, has been clinically proven to increase NAD+ levels. The Tru Niagen dietary supplement comprises food-grade Niagen, the company’s flagship patented nicotinamide riboside ingredient.
Investment managers and institutional investors widely use Russell indexes for index funds and as benchmarks for active investment strategies. Approximately US$10.5 trillion in assets are benchmarked against Russell’s US indexes.
Meanwhile, bioscience company Chr. Hansen, now part of Novonesis, adjusted its organic growth financial outlook upwards of 9-11%, following a healthy performance for the first three quarters of 2023. Revenue amounted to €335 million (US$365 million), up 5% from €318 million (US$346 million) the previous financial year.
By Inga de Jong
